Cardionomic

Cardionomic, founded with the mission to transform the treatment of Acute Decompensated Heart Failure (ADHF), focuses on innovative neuromodulation therapies. The company aims to address the root cause of reduced cardiac output by targeting the terminal branches of the cardiac plexus, thereby improving cardiac output, renal blood flow, and urine production. Their acute, non-systemic therapy also reduces plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), biomarkers of chronic heart failure, enhancing pharmacological tolerance.

Notable figures associated with Cardionomic include a distinguished management team and board of directors with extensive experience in medical technology and cardiology. The company has achieved significant milestones in clinical studies, demonstrating the efficacy of their investigational device. Cardionomic's impact lies in its potential to offer a novel, effective treatment for ADHF, promising improved patient outcomes and advancing the field of cardiac care.